Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells

References

• Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta. 2007;1773:642–652.
   PubMed Web of Science ®Google Scholar
• Kunigal S, Gondi CS, Gujrati M, et al. SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol. 2006;29:1349–1357.
   PubMed Web of Science ®Google Scholar
• Gutierrez LS, Schulman A, Brito-Robinson T, et al. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. 2000;60:5839–5847.
   PubMed Web of Science ®Google Scholar
• Salamone M, Carfi Pavia F, Ghersi G. Proteolytic enzymes clustered in specialized plasma-membrane domains drive endothelial cells’ migration. PloS one. 2016;11:e0154709.
   PubMed Web of Science ®Google Scholar
• Chand HS, Foster DC, Kisiel W. Structure, function and biology of tissue factor pathway inhibitor-2. Thromb Haemost. 2005;94:1122–1130.
   PubMed Web of Science ®Google Scholar
• Izumi H, Takahashi C, Oh J, et al. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett. 2000;481:31–36.
   PubMed Web of Science ®Google Scholar
• Kondraganti S, Gondi CS, Gujrati M, et al. Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol. 2006;29:25–32.
   PubMed Web of Science ®Google Scholar
• Tang Z, Geng G, Huang Q, et al. Expression of tissue factor pathway inhibitor 2 in human pancreatic carcinoma and its effect on tumor growth, invasion, and migration in vitro and in vivo. J Surg Res. 2011;167:62–69.
   PubMed Web of Science ®Google Scholar
• Williams L, Tucker TA, Koenig K, et al. Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice. Am J Respir Cell Mol Biol. 2012;46:173–179.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Yagyu T, Inagaki K, et al. Bikunin plus paclitaxel markedly reduces tumor burden and ascites in mouse model of ovarian cancer. Int J Cancer. 2004;110:134–139.
   PubMed Web of Science ®Google Scholar
• Bayraktar E, Igci M, Erturhan S, et al. Reduced gene expression of bikunin as a prognostic marker for renal cell carcinoma. Exp Oncol. 2014;36:107–111.
   PubMedGoogle Scholar
• Muller SM, Okan E, Jones P. Regulation of urokinase receptor transcription by Ras- and Rho-family GTPases. Biochem Biophys Res Commun. 2000;270:892–898.
   PubMed Web of Science ®Google Scholar
• Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11:23–36.
   PubMed Web of Science ®Google Scholar
• Hall A. Rho family GTPases. Biochem Soc Trans. 2012;40:1378–1382.
   PubMed Web of Science ®Google Scholar
• Gerthoffer WT. Mechanisms of vascular smooth muscle cell migration. Circ Res. 2007;100:607–621.
   PubMed Web of Science ®Google Scholar
• Margheri F, Luciani C, Taddei ML, et al. The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style. Oncotarget. 2014;5:1538–1553.
   PubMedGoogle Scholar
• Balsara RD, Merryman R, Virjee F, et al. A deficiency of uPAR alters endothelial angiogenic function and cell morphology. Vasc Cell. 2011;3:10.
   PubMedGoogle Scholar
• Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem. 2004;37:541–548.
   PubMed Web of Science ®Google Scholar
• Degryse B, Resnati M, Rabbani SA, et al. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. Blood. 1999;94:649–662.
   PubMed Web of Science ®Google Scholar
• Sid B, Dedieu S, Delorme N, et al. Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator. Int J Biochem Cell Biol. 2006;38:1729–1740.
   PubMed Web of Science ®Google Scholar
• Czekay RP, Wilkins-Port CE, Higgins SP, et al. PAI-1: an integrator of cell signaling and migration. Int J Cell Biol. 2011;2011:562481.
   PubMedGoogle Scholar
• Morais KL, Pacheco MT, Berra CM, et al. Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell. Mol Cell Biochem. 2016;415:119–131.
   PubMed Web of Science ®Google Scholar
• Pacheco MT, Berra CM, Morais KL, et al. Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X. PloS one. 2014;9:e111907.
   PubMed Web of Science ®Google Scholar
• Pacheco MT, Morais KL, Berra CM, et al. Specific role of cytoplasmic dynein in the mechanism of action of an antitumor molecule, Amblyomin-X. Exp Cell Res. 2016;340:248–258.
   PubMed Web of Science ®Google Scholar
• de Souza JG, Morais KL, Angles-Cano E, et al. Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model. Oncotarget. 2016;7:62255–62266.
   PubMedGoogle Scholar
• Chudzinski-Tavassi AM, Morais KL, Pacheco MT, et al. Tick salivary gland as potential natural source for the discovery of promising antitumor drug candidates. Biomed Pharmacother. 2016;77:14–19.
   PubMed Web of Science ®Google Scholar
• Branco VG, Iqbal A, Alvarez-Flores MP, et al. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo. Biochim Biophys Acta. 2016;1864:1428–1435.
   PubMed Web of Science ®Google Scholar
• Katia LP, Morais KFMP. Mario Thiego Fernandes Pacheco, Carolina Maria Berra, Miryam Paola Alvarez-Flores, and Ana Marisa Chudzinski-Tavassi. Rational development of a novel TFPI-like inhibitor from Amblyomma cajennense tick. Toxin Rev. 2013;33:48–52.
   Google Scholar
• Maria DA, de Souza JG, Morais KL, et al. A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production. Invest New Drugs. 2013;31:493–505.
   PubMed Web of Science ®Google Scholar
• Drewes CC, Dias RY, Branco VG, et al. Post-transcriptional control of Amblyomin-X on secretion of vascular endothelial growth factor and expression of adhesion molecules in endothelial cells. Toxicon. 2015;101:1–10.
   PubMed Web of Science ®Google Scholar
• Hembrough TA, Ruiz JF, Papathanassiu AE, et al. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem. 2001;276:12241–12248.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Suzuki M, Kanayama N, et al. Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade. Eur J Biochem. 2002;269:3945–3957.
   PubMedGoogle Scholar
• Baranowska K, Misund K, Starheim KK, et al. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells. Oncotarget. 2016;7:70845–70856.
   PubMedGoogle Scholar
• Hambley B, Caimi PF, William BM. Bortezomib for the treatment of mantle cell lymphoma: an update. Ther Adv Hematol. 2016;7:196–208.
   PubMed Web of Science ®Google Scholar
• Niewerth D, Kaspers GJ, Jansen G, et al. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. J Hematol Oncol. 2016;9:82.
   PubMed Web of Science ®Google Scholar
• Castro TB, Hallack Neto AE, Atalla A, et al. Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide. Braz J Med Biol Res = Revista brasileira de pesquisas medicas biologicas/Sociedade Brasileira de Biofisica [et al]. 2016;49:e5128.
   Google Scholar
• Lu P, Takai K, Weaver VM, et al. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011;3:a005058.
   PubMed Web of Science ®Google Scholar
• Nagai S, Nakamura M, Yanai K, et al. Gli1 contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. Cancer Sci. 2008;99:1377–1384.
   PubMed Web of Science ®Google Scholar
• Badgwell DB, Lu Z, Le K, et al. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene. 2012;31:68–79.
   PubMed Web of Science ®Google Scholar
• Batista IF, Ramos OH, Ventura JS, et al. A new Factor Xa inhibitor from Amblyomma cajennense with a unique domain composition. Arch Biochem Biophys. 2010;493:151–156.
   PubMed Web of Science ®Google Scholar
• Jaffe EA, Nachman RL, Becker CG, et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745–2756.
   PubMed Web of Science ®Google Scholar
• Toth M, Fridman R. Assessment of Gelatinases (MMP-2 and MMP-9 by Gelatin Zymography. Methods Mol Med. 2001;57:163–174.
   PubMedGoogle Scholar